Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01301963 · ClinicalTrials.gov registry record · Phase 3
Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide
A Phase 3 study, sponsored by Case Comprehensive Cancer Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 9
- Enrollment target
NCT01301963 is a Phase 3 study that was terminated before completion, run by Case Comprehensive Cancer Center. The registered enrollment target is 9 participants.
The verdict
NCT01301963, a Phase 3 study, was terminated before completion, sponsored by Case Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 9 participants
- Enrollment target
Study Summary
This clinical trial studies filgrastim (G-CSF) with or without plerixafor in treating patients with multiple myeloma (MM) previously treated with lenalidomide. Giving colony-stimulating factors, such as G-CSF, and plerixafor helps stem cells move from the patient's bone marrow to the blood so they can be collected and stored
Interventions
- BIOLOGICAL filgrastim
- DRUG plerixafor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2011-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01301963
The ClinicalTrials.gov registry entry for NCT01301963 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which filgrastim is the first listed.
NCT01301963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01301963 about?
NCT01301963 is a clinical study titled "Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide". This clinical trial studies filgrastim (G-CSF) with or without plerixafor in treating patients with multiple myeloma (MM) previously treated with lenalidomide. Giving colony-stimulating factors, such as G-CSF, and plerixafor helps stem cells move from the patient's bone marrow to the blood so they c...
What is the current status of trial NCT01301963?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 9 participants. The study started on 2011-07.
What interventions are being tested in trial NCT01301963?
The interventions under investigation include: filgrastim (BIOLOGICAL), plerixafor (DRUG).
Who is sponsoring clinical trial NCT01301963?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.